Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 14/20 | 0.61 |
| ▸ | EHMT1 | Q9H9B1 | 14/20 | 0.61 |
| ▸ | SPIN1 | Q9Y657 | 2/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.52 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2924579 | 0.99 | EHMT2 (0.60) | EHMT2EHMT1SPIN1KDRTLR9 | |
| SCHEMBL5498950 | 0.94 | EHMT2 (0.54) | EHMT2EHMT1SPIN1KDR | |
| SCHEMBL4380551 | 0.93 | EHMT2 (0.53) | EHMT2EHMT1SPIN1KDR | |
| SCHEMBL4025116 | 0.92 | EHMT2 (0.52) | EHMT2EHMT1KDRTLR9TLR7 | |
| SCHEMBL4379749 | 0.90 | EHMT2 (0.50) | EHMT2EHMT1SPIN1KDR | |
| SCHEMBL1734721 | 0.90 | KDM1A (0.57) | KDR | |
| SCHEMBL829762 | 0.90 | KDM1A (0.57) | KDR | |
| SCHEMBL29478513 | 0.90 | KDM1A (0.57) | KDR | |
| SCHEMBL29478512 | 0.90 | KDM1A (0.57) | KDR | |
| Hydrochloric Acid SCHEMBL4378504 | 0.89 | KDM1A (0.56) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1381599-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-09-24 | — | — | EP | disclosed |
| US-7223756-B2 | Quinazoline compounds with therapeutic use | ASTRAZENECA AB (SE) | 2007-05-29 | — | — | US | disclosed |
| EP-1453492-B1 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-01-24 | — | — | EP | disclosed |
| US-7157467-B2 | Administering compound such as 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-morpholinopropoxy)quinazoline for therapy of an autoimmune disease or medical condition selected from transplant rejection and rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-02 | — | — | US | disclosed |
| US-7141577-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2006-11-28 | — | — | US | disclosed |
| US-7115615-B2 | Quinazoline derivatives | ASTRAZENECA (SE) | 2006-10-03 | — | — | US | disclosed |
| US-6939866-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2005-09-06 | — | — | US | disclosed |
| US-6849625-B2 | Quinazoline derivatives with anti-tumour activity | ASTRAZENECA AB (SE) | 2005-02-01 | — | — | US | disclosed |
| US-20050014773-A1 | Therapeutic use | ASTRAZENACA AB (SE) | 2005-01-20 | — | — | US | disclosed |
| US-20050009850-A1 | Quinazoline compounds with therapeutic use | ASTRAZENECA AB (SE) | 2005-01-13 | — | — | US | disclosed |
| US-20040138240-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | US | disclosed |
| US-20040048881-A1 | Quinazoline derivatives with anti-tumour activity | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | US | disclosed |
| US-20040044015-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044015-A1 | Quinazoline derivatives | NQO2, NRAS, TOP1 | EHMT2 3178/4885EHMT1 2404/4885SPIN1 2171/4885 |
| US-20040138240-A1 | Quinazoline derivatives | NQO2, WEE1, CMA1 | EHMT2 1923/4885EHMT1 888/4885SPIN1 2858/4885 |
| US-20040048881-A1 | Quinazoline derivatives with anti-tumour activity | TOP1, NQO2, ABCC1 | EHMT2 3414/4885EHMT1 2291/4885SPIN1 2133/4885 |
| US-20050009850-A1 | Quinazoline compounds with therapeutic use | CD4, HLA-DRB1, IL5 | EHMT2 2260/4885EHMT1 1036/4885SPIN1 3787/4885 |
| US-20050014773-A1 | Therapeutic use | CD4, HLA-DRB1, CD74 | EHMT2 1834/4885EHMT1 945/4885SPIN1 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.